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Reply to Flawed Assumptions
Used to Defend Screening
Mammography
We are pleased to have the opportunity to respond to
Bleyer et al. As our recent article1 in Cancer shows and
their comments confirm, the assessment of changes in
breast cancer stages over long time periods and the impli-
cations for the overdiagnosis of invasive cancer hinge sen-
sitively on assumptions about the trend in background
breast cancer incidence rates. We provided various meas-
ures of background incidence trends in the absence of
screening mammography, cited other estimates from the
literature, and modeled a range of annual percentage
change (APC) values from 0.5% to 2.0%. Our article
shows that a reasonable background incidence increase,
independent of screening mammography, leads to a
reduction in late-stage disease. It is, therefore, not surpris-
ing that the authors of the letter argue that our assumption
of a background incidence APC increase in US women
from 1977-1979 to 2007-2009 is too high. Bleyer and
Welch’s estimate of overdiagnosis assumed an increase of
0.25% per year on the basis of background trends for
women less than 40 years old.2
In fact, our assumption of a 0.5% to 2.0% APC is
quite modest. Our article cites numerous published exam-
ples of APCs in excess of our central estimate of 1.3%
among unscreened women.1 Additional recent publica-
tions support the reasonableness of our central estimate:
1. National Cancer Institute–funded Cancer Intervention
and Surveillance Modeling Network (CISNET) mod-
els estimated background breast cancer mortality
trends absent screening mammography and adjuvant
therapy from 1975 to 2000.3 The median of 7 different
CISNET models estimated a 31% expected increase in
the mortality rate secondary to background incidence
trends or an average increase of 1.2% per year.
2. In Iceland, where population-based screening began
in late 1987, over the prescreening period of 1969-
1987, the breast cancer incidence for women who
were 40 to 69 years increased 1.4% per year.4
Twenty-three years after screening began, the inva-
sive cancer incidence was 11% lower than expected
on the basis of prescreening incidence trends. This
reduction in the incidence of invasive cancer after
screening is nearly identical to our 9% reduction
estimate at an APC of 1.3%.
3. In Denmark, where a national screening program did
not begin until 2008-2010, among women who were
50 to 69 years and were not offered screening from
1990 to 2007, the breast cancer incidence increased
3% per year, which is more than double our estimate.5
In addition, an overdiagnosis rate of 4% was reported.5
4. World data from the International Agency for Research
on Cancer of the World Health Organization between
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2008 and 2012 showed a 20% (or 4% per year)
increase in the incidence of breast cancer and a 14% (or
2.8% per year) mortality rate increase.6 The agency
noted specifically that the “marked increase in breast
cancers must be addressed” and attributed the
increased mortality in part to an increased incidence.
Directly germane to the APC estimates in refer-
ence to late-stage disease incidence is a recent study,
coauthored by Bleyer, which demonstrated an APC of
2.1% for the most lethal type of late-stage breast can-
cer, that with distant involvement at presentation,
among women 25 to 39 years old.7 If this background
cancer incidence APC estimate had been used in our
study, the projected decrease in distant disease would
have exceeded 40%.
The authors of the letter lead the reader to believe
that by 1982, clinical screening mammography in the
United States was well underway and, therefore, was a
major contributor to the increasing incidence trend. That
was not the case. An analysis of long-term secular inci-
dence trends in Connecticut from 1940 showed an
upward inflection point of the existing trend, which was
attributed to the onset of screening mammography, after
1982, not before.8 Breast cancer incidence rates increased
by an average of 1.3% per year from 1941-1945 to 1966-
1970, many years before clinical mammographic screen-
ing in the United States.9
The referenced “national breast cancer detection
demonstration program” was an experimental program
that ran from 1973 to 1980 and screened 283,222 women
who were 35 to 74 years (0.6% of women who were 35-
74 years old). After the Breast Cancer Detection Demon-
stration Project ended in 1980, there was no national
screening program and very little screening. Medicare did
not begin funding screening mammography until 1991.
From 1977 to 1982, much mammography in the United
States was diagnostic mammography. Sites offering mam-
mography often did not distinguish between screening
and diagnostic mammography. Bleyer et al cite Howard10
stating that “by the end of the [1977-1982] interval at
least 5-10% of women in the U.S. were screened.”
Howard did not state this, instead stating “it is difficult to
determine the extent to which mammographic examina-
tions have been performed for screening rather than diag-
nostic purposes. There is, therefore, an element of
uncertainty in estimating the proportion of women who
have been screened with mammography at some time in
their lives and the proportion that are routinely screen-
ed.”10 Other data, when screening mammography and
diagnostic mammography were tracked separately during
those years, confirm that “less than 5% of women aged 45
years and older underwent the [screening] procedure each
year.”11
The authors of the letter suggest that the most
reliable data for establishing a nonscreened background
incidence trend among older women are data for women
less than 40 years old. We have provided published sour-
ces that suggest otherwise. Feuer and Wun8 showed that
before 1982, APCs in the United States differed by age.
Women who were 40 to 49 years old had an APC of
0.8%, and women who were 60 to 69 years old had an
APC nearly double that of 1.51%. Similarly, data from
the United Kingdom before the onset of screening, shown
in Table 1 of our article,1 show that women less than 40
years old had an APC of 1.1% (similar to what we
assumed for US women who were 401 years old),
whereas UK women who were 501 years old had an APC
approximately twice that (2.1% for women who were
50-64 years old, 1.8% for women who were 65-69 years
old, and 2.3% for women who were 701 years old).
Attributions of overdiagnosis or underdiagnosis of
invasive cancer to mammographic screening rely on
knowledge of the actual screening status of women with
breast cancer. Because Surveillance, Epidemiology, and
End Results (SEER) data do not track the screening status,
estimates of overdiagnosis based exclusively on SEER data
are limited.
The last statement of the letter is incorrect. Mark A.
Helvie, Joanne T. Chang, and Mousumi Banerjee are not
paid consultants of GEHealthcare.
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